Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BCMA

BCMA

Brief Information

Name:B-cell maturation protein
Target Synonym:B-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:58
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
BCA-HA2H4 Human APC-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HA2H4-structure
BCA-HP2H7 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HP2H7-structure
BCA-C5257 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag (MALS verified)
BCA-C5257-structure
BCA-C5257-sds
BCA-HF2H3 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HF2H3-structure
BCA-HF2H3-sds
BCA-C52H3 Canine Canine BCMA / TNFRSF17 Protein,His Tag (MALS verified)
BCA-C52H3-structure
BCA-C52H3-sds
BCA-R52H3 Rat Rat BCMA / TNFRSF17 Protein,His Tag
BCA-R52H3-structure
BCA-R52H3-sds
BCA-R52H4 Rabbit Rabbit BCMA / TNFRSF17 Protein,His Tag
BCA-R52H4-structure
BCA-R52H4-sds
BCA-HP2H2 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation) DMF Filed
BCA-HP2H2-structure
BCA-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His,Avitag™
BCA-C82E5-structure
BCA-C82E5-sds
BCA-M43 Mouse Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43-sds
MBS-K004 Human Human BCMA-coupled Magnetic Beads
BCA-HF2H1 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His Tag DMF Filed
BCA-HF2H1-structure
BCA-HF2H1-sds
BCA-H5253 Human Human BCMA / TNFRSF17 Protein, Mouse IgG2a Fc Tag, low endotoxin
BCA-H5253-structure
BCA-H5253-sds
BCA-M52H3 Mouse Mouse BCMA / TNFRSF17 Protein, His Tag
BCA-M52H3-structure
BCA-M52H3-sds
BCA-H82E4 Human Biotinylated Human BCMA / TNFRSF17 Protein, His,Avitag™ DMF Filed
BCA-H82E4-structure
BCA-H82E4-sds
BCA-H5259 Human Human BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low endotoxin
BCA-H5259-structure
BCA-H5259-sds
BCA-C52H7 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His Tag
BCA-C52H7-structure
BCA-C52H7-sds
BCA-M82F0 Mouse Biotinylated Mouse BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-M82F0-structure
BCA-M82F0-sds
BCA-M5258 Mouse Mouse BCMA / TNFRSF17 Protein, Fc Tag
BCA-M5258-structure
BCA-M5258-sds
BCA-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag
BCA-C5253-structure
BCA-C5253-sds
BCA-C82F4 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-C82F4-structure
BCA-C82F4-sds
BC7-H82F0 Human Biotinylated Human BCMA / TNFRSF17 Protein, Fc,Avitag™ DMF Filed
BC7-H82F0-structure
BC7-H82F0-sds
BCA-H522y Human Human BCMA / TNFRSF17 Protein,His Tag (HPLC-verified) DMF Filed
BCA-H522y-structure
BCA-H522y-sds
BCA-H522y-hplc
BCA-HF254 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, Fc Tag DMF Filed
BCA-HF254-structure
BCA-HF254-sds
BC7-H5254 Human Human BCMA / TNFRSF17 Protein, Fc Tag (HPLC verified) DMF Filed
BC7-H5254-structure
BC7-H5254-sds
BC7-H5254-hplc

Part of Bioactivity data

BCA-HA2H4-Cell-based assay
Evaluation of CAR expression

5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H4) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).

BCA-M43-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCA-H522y-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human BCMA MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 13.0 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

TNFRSF17,CD269,BCM,BCMA

Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Idecabtagene vicleucel bb-2121 Approved Bluebird Bio Abecma Japan Multiple Myeloma Bristol-Myers Squibb Kk 2021-03-26 Multiple Myeloma Details
Belantamab mafodotin GSK-2857916; GSK2857916 Approved Glaxosmithkline Plc BLENREP EU Multiple Myeloma Glaxosmithkline (Ireland) Ltd 2020-08-05 Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Multiple Myeloma Details
Anti-BCMA/CD19 CAR-T(Autolus) Phase 1 Clinical Multiple Myeloma Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma Details
P-BCMA-101 P-BCMA-101 Phase 2 Clinical Poseida Therapeutics Multiple Myeloma Details
LCAR-B4822M LCAR-B4822M Phase 1 Clinical Genscript Biotech Corp Multiple Myeloma Details
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
MCM-998 MCM-998; LXG-250 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
KITE-585 KITE-585 Phase 1 Clinical Kite Pharma, National Cancer Institute Multiple Myeloma Details
BCMA CAR-T Cells (Pregene) PRG-1801 Phase 1 Clinical Shenzhen Prekin Biopharmaceutical Co Ltd Multiple Myeloma Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Multiple Myeloma Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) CBG-002 CAR-T Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) Phase 3 Clinical The First Affiliated Hospital Of Soochow University Multiple Myeloma Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) Phase 1 Clinical Multiple Myeloma Details
SEA-BCMA SEA-BCMA; SGN-BCMA Phase 1 Clinical Seattle Genetics Multiple Myeloma Details
PBCAR-269A PBCAR-269A Phase 2 Clinical Precision Biosciences Multiple Myeloma Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase 1 Clinical Shengyan Pharmaceutical Technology Multiple Myeloma Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) Phase 1 Clinical Sichuan University Multiple Myeloma Details
HBI-0101 HBI-0101 Phase 1 Clinical Hadassah Medical Organization Details
lentiviral transfected chimeric antigen receptor T-cells(Icell Gene) Icell Gene Therapeutics Details
C-CAR088 C-CAR088 Phase 1 Clinical Cellular Biomedicine (Shanghai) Co Ltd Multiple Myeloma Details
CC-99712 CC-99712 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
MEDI-2228 MEDI-2228 Phase 1 Clinical Medimmune Llc Multiple Myeloma Details
CC-98633 CC-98633 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) Phase 2 Clinical Asclepius Technology Company Group Multiple Myeloma Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) Clinical Wuhan Bio-Raid Biotechnology Hematologic Neoplasms Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma Details
ACTR 087/SEA BCMA combination therapy Phase 1 Clinical Unum Therapeutics Multiple Myeloma Details
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) Bioray Laboraytories Inc Details
GC-012F GC-012F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Multiple Myeloma Details
JWCAR129 JWCAR129; JWCAR-129 Phase 1 Clinical Suzhou Yaomingjunuo Biotechnology Co Ltd Multiple Myeloma Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) LCAR-BCX Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Multiple Myeloma Details
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) Clinical Hebei Senlang Biological Technology Co Ltd Multiple Myeloma Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) Phase 1 Clinical Persongen Biotherapeutics Multiple Myeloma Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 1 Clinical The First Affiliated Hospital Of Nanchang University Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) Clinical Huazhong University Of Science And Technology Multiple Myeloma Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Multiple Myeloma Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) Descartes-08 Phase 2 Clinical Cartesian Therapeutics Myasthenia Gravis; Multiple Myeloma Details
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology POEMS Syndrome Details
Anti-BCMA CAR T-cell therapy (Arcellx) CART-ddBCMA Phase 1 Clinical Arcellx Multiple Myeloma Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase 1 Clinical Hrain Biotechnology Co Ltd Multiple Myeloma Details
CTX-120 CTX-120 Phase 1 Clinical Crispr Therapeutics Multiple Myeloma Details
Pacanalotamab AMG-420; BI-836909 Phase 1 Clinical Micromet Multiple Myeloma Details
ALLO-605 ALLO-605; ALLO605 Phase 2 Clinical Allogene Therapeutics Inc Multiple Myeloma Details
ALLO-715 ALLO-715 Phase 1 Clinical Allogene Therapeutics Inc, Cellectis Multiple Myeloma Details
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Multiple Myeloma Details
AMG-224 AMG-224 Phase 1 Clinical Amgen Inc Multiple Myeloma Details
EMB-06(Shanghai Epimab Biotherapeutics) EMB-06; EMB06 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Multiple Myeloma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Alnuctamab CC-93269; EM-901 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
CM-336(Connaught Biomedical Technology) CM-336 Phase 1 Clinical Keymed Biosciences Co Ltd Multiple Myeloma Details
REGN-5459 REGN-5459 Phase 2 Clinical Regeneron Pharmaceuticals Inc Multiple Myeloma; Renal Insufficiency, Chronic Details
Orvacabtagene autoleucel ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 Phase 2 Clinical Juno Therapeutics Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
PHE-885 PHE-885 Phase 2 Clinical Novartis Pharma Ag Hematologic Neoplasms; Multiple Myeloma Details
GR-1803 GR-1803 Phase 1 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Multiple Myeloma Details
BCMA-NKE BCMA-NKE Phase 1 Clinical Bristol-Myers Squibb Company Multiple Myeloma Details
Zevorcabtagene Autoleucel CT-053-CARsgen Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Multiple Myeloma Details
bb-21217 bb-21217 Phase 1 Clinical Bristol-Myers Squibb Company, Bluebird Bio Multiple Myeloma Details
TNB-383B TNB-383B; ABBV-383 Phase 1 Clinical Teneobio, Abbvie Inc Multiple Myeloma Details
BCMA TriTAC HPN-217 Phase 2 Clinical Harpoon Therapeutics, Abbvie Inc Multiple Myeloma Details
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) CT-103A; CT103A; IBI-326 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd Multiple Myeloma; Neuromyelitis Optica Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) Phase 1 Clinical Shandong New Time Pharmaceutical Co Ltd Multiple Myeloma Details
Pavurutamab AMG-701 Phase 1 Clinical Amgen Inc Multiple Myeloma Details
Elranatamab PF-06863135 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Bone Marrow Neoplasms; Multiple Myeloma Details
Humanized CART Directed Against BCMA ARI-0002h Instituto De Salud Carlos Iii Details
FT-576 FT-576 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Bone Marrow Neoplasms; Multiple Myeloma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message